19.12 - F. Gardoni, Università di Milano

Condividi su
Data dell'evento: 19/12/2014
milano_torino_2

Venerdì 19 dicembre - ore 14:00
Aula seminari, NICO

GluN2A-containing NMDA receptors as synaptic trait of levodopa-induced dyskinesias: from experimental models to patients
Fabrizio Gardoni
Dipartimento di Scienze Farmacologiche e Biomolecolari, Università di Milano

Levodopa (L-DOPA)-induced dyskinesias (LIDs) are a major complication in the pharmacological management of Parkinson's Disease (PD). Abnormal glutamatergic transmission in striatum is considered a key factor in the development of LIDs.

gardoni

Here we show that an altered ratio of synaptic GluN2A/GluN2B-containing NMDA receptors (NMDARs) in striatum represents a common trait in L-DOPA-treated dyskinetic animals (6-OHDA rats and MPTP monkeys) and in post-mortem tissue from dyskinetic PD patients. The modulation of synaptic NMDAR composition by cell-permeable peptides interfering with GluN2A subunit clustering at postsynaptic sites leads to a reduction in the dyskinetic motor behavior in the two animal models of LIDs.

Our results indicate that targeting synaptic NMDAR subunit composition may represent an intriguing therapeutic approach aimed at ameliorating L-DOPA motor side effects.

Host: Alessandro Vercelli

download pdf

Agenda

06 novembre 2018

ZEISS Academy Workshop – Microscopia Correlativa 3D

Le ultime novità nella Microscopia Correlativa Multi-modale. Registrazione obbligatoria.

16 febbraio 2019

Torino - 10th International Meeting STEROIDS and NERVOUS SYSTEM

Since 2001, this meeting represented an important event for basic and clinical researchers working on this emerging scientific topic. We will address state-of-the-art approaches in the field of steroids and nervous system, including behavior, epigenetics, genomic and non-genomic actions, the vitamin D, neurodegenerative and psychiatric disorders, and the interference among endocrine disruptors and steroid signaling.

Ricerca

Identificato un nuovo bersaglio per contrastare la SMA

L’inibizione della proteina JNK rallenta la progressione della malattia che colpisce i motoneuroni ed è la prima causa genetica di morte nell’infanzia. Lo dimostra uno studio pubblicato su Frontiers in Molecular Neuroscience dal nostro gruppo di ricerca guidato da Alessandro Vercelli, in collaborazione con l’Istituto Mario Negri di Milano. Chiarire i meccanismi molecolari alla base della SMA può aprire la strada allo sviluppo di nuove terapie.

24 ottobre 2018